HRS9531 Controls Weight Regain in Obese Subjects

PHASE2Active, not recruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

January 1, 2024

Primary Completion Date

June 30, 2025

Study Completion Date

December 31, 2025

Conditions

Obesity

Interventions

DRUG

HRS9531

HRS9531 escalated to the protocol-specified dose once weekly injection for 24 weeks ，then low frequency injection for 12 weeks.

DRUG

HRS9531 placebo

HRS9531 placebo low frequency injection for 12 weeks.

Trial Locations (1)

Xiaoying Li, Shanghai

All Listed Sponsors

lead

Shanghai Zhongshan Hospital

OTHER

NCT06287437 - HRS9531 Controls Weight Regain in Obese Subjects | Biotech Hunter | Biotech Hunter